Percepta: Rough prioritization of compounds for inhalation vs oral routes

Description
Some programs consider multiple administration routes (e.g., inhalation vs oral). While Percepta does not model route‑specific PK directly, basic properties (solubility, lipophilicity, volatility, ionization) can inform a qualitative prioritization.

Solution

1. For each compound, obtain Percepta predictions for:
   • logP/logD at physiological pH.
   • Aqueous solubility.
   • pKa.
   • Vapor pressure / volatility indicators (if available in your setup).
2. Conceptual tendencies:
   • Oral: need adequate solubility and balanced lipophilicity for absorption and formulation.
   • Inhalation: volatility, particle behavior, and local tolerability matter; extremely lipophilic or very low‑solubility compounds may pose formulation challenges.
3. Use these predicted properties to:
   • Flag compounds that are clearly unsuitable for one route (e.g., extremely low solubility for oral with no viable formulation concept).
   • Highlight compounds with more favorable property ranges for each route.
4. Discuss with formulation and DMPK experts to decide which compounds warrant detailed route‑specific experiments.
5. Document that Percepta‑based assessments are qualitative and must be verified with appropriate in vitro and in vivo studies.